ALF and USV evaluations 2022
During 2022, two national evaluations of clinical research, education and development of healthcare will be conducted in accordance with the ALF agreements.
Both the Swedish Research Council's evaluation of the quality of clinical research and the National Board of Health and Welfare's evaluation of university healthcare are based on the ALF agreements. The evaluations will begin in January and run throughout 2022.
Why are evaluations important?
The ALF and USV evaluations are of great importance for everyone in the Stockholm region who works with clinical research and/or education. The outcome of these evaluations will affect the scope of ALF funding for clinical research in the next period, and are thus of great significance. High marks in these ALF evaluations are also important in consolidating Stockholm's position as a leading region in Life Science, and for realising the ambition to become one of the world's five leading life science regions by 2025.
Read more about each evaluation:
A steering group representing the Karolinska Institutet-Region Stockholm management team shares responsibility for the documentation submitted for the ALF and USV evaluations.
The steering group consists of:
- Anders Gustafsson, Vice President KI
- Clara Hellner, Director Research & Innovation Region Stockholm
- Annika Tibell, Director Research, Development, Education & Innovation Karolinska University Hospital
- Annika Östman Wernerson, Academic Vice President of Higher Education, KI
- Kerstin Lundin, Project Leader, KI
- Viktoria Svensson, Coordinator, KI
- Maria Schönnings, Coordinator, KI
- Viktoria Björk, Manager, Research, Development, Education & Innovation, Karolinska University Hospital
- Carl Sundström, Coordinator, KI
A specific working group supports the USV units in the evaluation of university healthcare and reports to the steering group.